ACM
NEUP

ADAR1 Capital Management’s Neuphoria Therapeutics NEUP Stock Holding History

ADAR1 Capital Management’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$122K Hold
30,000
– – 0.01% 281
2025
Q4 		$116K Buy
+30,000
New +$213K 0.01% 246

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

ADAR1 Capital Management's NEUP Position: Q1 2026 in Review

ADAR1 Capital Management held its Neuphoria Therapeutics (NEUP) position steady in Q1 2026 at 30,000 shares worth $122K. The position accounts for 0.01% of the portfolio, ranked #281.

ADAR1 Capital Management first reported a position in NEUP in Q4 2025 and has held it in 2 quarters since. 19 funds tracked by Wall St. Rank hold NEUP as of Q1 2026.

  • ADAR1 Capital Management held 30,000 shares of Neuphoria Therapeutics worth $122K as of Q1 2026.
  • ADAR1 Capital Management left its Neuphoria Therapeutics share count unchanged in Q1 2026.
  • Neuphoria Therapeutics made up 0.01% of ADAR1 Capital Management's portfolio in Q1 2026, its #281 holding.
  • ADAR1 Capital Management first reported a position in Neuphoria Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 19 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.